Probing the Higgs self coupling via single Higgs production at the LHC

We propose a method to determine the trilinear Higgs self coupling that is alternative to the direct measurement of Higgs pair production total cross sections and differential distributions. The method relies on the effects that electroweak loops featuring an anomalous trilinear coupling would imprint on single Higgs production at the LHC. We first calculate these contributions to all the phenomenologically relevant Higgs production ($gg{\rm F}$, VBF, $WH$, $ZH$, $t\bar tH$) and decay ($\gamma \gamma$, $WW^{*}/ZZ^{*}\to 4f$, $b\bar b$, $\tau \tau$) modes at the LHC and then estimate the sensitivity to the trilinear coupling via a one-parameter fit to the single Higgs measurements at the LHC 8 TeV. We find that the bounds on the self coupling are already competitive with those from Higgs pair production and will be further improved in the current and next LHC runs.Comment: 34 pages, 13 figures, 5 tables; V2: New appendix A added on the comparison with the Effective Field Theory approach; V3: Journal versio

Attitude of Italian medical oncologists toward palliative care for patients with advanced cancer: results of the SIO project.

The aim of this survey was to describe the attitude of Italian oncologists towards palliative care. A survey on palliative care was carried out among 400 Italian oncologists. Seventy-two percent indicated that the management of patients with advanced stage cancer represents the majority of their practice. They are often involved in the management of pain (78%) and complications of chemotherapy (61%), and frequently, in the treatment of terminal patients (60%). Only 8.5% reported having frequent collaboration with psychiatrists in support of emotional and psychological patients' disturbances. About 40% are often directly involved in the management of existential or spiritual distress. Discussions on euthanasia and assisted suicide, which are illegal in Italy, took place never (68%) or occasionally (27%). Respondents agreed that all oncology centres should have access to palliative care service. These results are in line with those of the European Society of Medical Oncology survey and may be usefully employed to improve the organisation of palliative care

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: Results from the ITACa trial

Serum levels of C-reactive protein are (CRP) higher in patients with neoplastic conditions and numerous studies have been performed to clarify the etiologic and prognostic role of the high-sensitivity CRP (hs-CRP) in cancer. Our study was conducted on patients enrolled in the prospective randomized "Italian Trial in Advanced Colorectal Cancer (ITACa)" to assess hs-CRP levels and their impact on overall survival (OS) and progression-free survival (PFS). Serum samples from 132 ITACa patients were collected at baseline and 2 months after starting first-line chemotherapy. The supernatant was immediately transferred to cryovials and stored at -80°C. After thawing, hs-CRP was measured with the Cobas c501 analyzer. High levels of hs-CRP (≥ 13.1 mg/L) were associated with poorer median PFS (p < 0.0001) and OS (p < 0.0001) than low hs-CRP levels (< 13.1 mg/L). hs-CRP values in 107 patients were evaluated again after 2 months of therapy, revealing that patients with low hs-CRP levels in both baseline and second serum samples had the best median PFS and OS. Our study confirms the prognostic value of hs-CRP in patients with metastatic colorectal carcinoma

Four-lepton production at hadron colliders: aMC@NLO predictions with theoretical uncertainties

We use aMC@NLO to study the production of four charged leptons at the LHC, performing parton showers with both HERWIG and Pythia6. Our underlying matrix element calculation features the full next-to-leading order $O(\alpha_S)$ result and the $O(\alpha_S^2)$ contribution of the $gg$ channel, and it includes all off-shell, spin-correlation, virtual-photon-exchange, and interference effects. We present several key distributions together with the corresponding theoretical uncertainties. These are obtained through a process-independent technique that allows aMC@NLO to compute scale and PDF uncertainties in a fully automated way and at no extra CPU-time costComment: 24 pages, 6 figure

Deadwood in forest stands close to old-growthness under Mediterranean conditions in the Italian Peninsula

Considering that indicators of old-growth features can vary across the European ecoregions, this paper provides some results to identify the distinctive traits of old-growth forests in the Mediterranean ecoregion. Deadwood occurrence as indicator of naturalness is investigated in some remote forest areas that have developed in absence of anthropogenic disturbance over the past few decades. Eleven study sites across the Italian peninsula were elected and records of deadwood were carried out in 1-ha size plots. Deadwood volume, deadwood types and decay stages were inventoried in the selected sites. The amounts of deadwood indicate a large variability among the investigated forest stands: the total volume ranged between 2 and 143 m3ha-1, with an average of 60 m3ha-1. Lying deadwood is the most abundant component of deadwood in the investigated forests, due to the natural mortality occurring in the stands in relation to the processes established in the last decades. On the contrary, stumps are the less represented type of deadwood in almost all the study areas. All the decay classes are present in each study site. The amount of deadwood in Southern Europe, even if lower than that reported for North and Central European countries, could have a different meaning due to the faster decay occurring in Mediterranean forest ecosystems. For this reason, old-growth features and the characteristics of each indicator should be framed and referred to well-defined climatic and biogeographic contexts. Distinctively, under the conditions here investigated, three main deadwood features prove to characterize forest stands close to old-growthness: a ratio of dead to living wood not lower than 10%; lying deadwood much more abundant than the standing one; large range of deadwood size and decay classes across all the deadwood components

Single-top t-channel hadroproduction in the four-flavour scheme with POWHEG and aMC@NLO

We present results for the QCD next-to-leading order (NLO) calculation of single-top t-channel production in the 4-flavour scheme, interfaced to Parton Shower (PS) Monte Carlo programs according to the POWHEG and MC@NLO methods. Comparisons between the two methods, as well as with the corresponding process in the 5-flavour scheme are presented. For the first time results for typical kinematic distributions of the spectator-b jet are presented in an NLO+PS approach.Comment: 16+1 pages, 8 figures, matches version accepted for publication in JHE

Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care)

n/

W and Z/gamma* boson production in association with a bottom-antibottom pair

We present a study of l\nu b\bar{b} and l+ l- b\bar{b} production at hadron colliders. Our results, accurate to the next-to-leading order in QCD, are based on automatic matrix-element calculations performed by MadLoop and MadFKS, and are given at both the parton level, and after the matching with the Herwig event generator, achieved with aMC@NLO. We retain the complete dependence on the bottom-quark mass, and include exactly all spin correlations of final-state leptons. We discuss the cases of several observables at the LHC which highlight the importance of accurate simulations.Comment: 18 pages, 12 figures. References updated, minor changes to the tex

International consensus on the management of metastatic gastric cancer:step by step in the foggy landscape: Bertinoro Workshop, November 2022

Background: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but a general agreement on managing oligometastatic disease has yet to be achieved. An international multi-disciplinary workshop was held in Bertinoro, Italy, in November 2022 to verify whether achieving a consensus on at least some topics was possible. Methods: A two-round Delphi process was carried out, where participants were asked to answer 32 multiple-choice questions about CT, laparoscopic staging and biomarkers, systemic treatment for different localization, role and indication of palliative care. Consensus was established with at least a 67% agreement. Results: The assembly agreed to define oligometastases as a “dynamic” disease which either regresses or remains stable in response to systemic treatment. In addition, the definition of oligometastases was restricted to the following sites: para-aortic nodal stations, liver, lung, and peritoneum, excluding bones. In detail, the following conditions should be considered as oligometastases: involvement of para-aortic stations, in particular 16a2 or 16b1; up to three technically resectable liver metastases; three unilateral or two bilateral lung metastases; peritoneal carcinomatosis with PCI ≤ 6. No consensus was achieved on how to classify positive cytology, which was considered as oligometastatic by 55% of participants only if converted to negative after chemotherapy. Conclusion: As assessed at the time of diagnosis, surgical treatment of oligometastases should aim at R0 curativity on the entire disease volume, including both the primary tumor and its metastases. Conversion surgery was defined as surgery on the residual volume of disease, which was initially not resectable for technical and/or oncological reasons but nevertheless responded to first-line treatment.</p

International consensus on the management of metastatic gastric cancer:step by step in the foggy landscape: Bertinoro Workshop, November 2022

Background: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but a general agreement on managing oligometastatic disease has yet to be achieved. An international multi-disciplinary workshop was held in Bertinoro, Italy, in November 2022 to verify whether achieving a consensus on at least some topics was possible. Methods: A two-round Delphi process was carried out, where participants were asked to answer 32 multiple-choice questions about CT, laparoscopic staging and biomarkers, systemic treatment for different localization, role and indication of palliative care. Consensus was established with at least a 67% agreement. Results: The assembly agreed to define oligometastases as a “dynamic” disease which either regresses or remains stable in response to systemic treatment. In addition, the definition of oligometastases was restricted to the following sites: para-aortic nodal stations, liver, lung, and peritoneum, excluding bones. In detail, the following conditions should be considered as oligometastases: involvement of para-aortic stations, in particular 16a2 or 16b1; up to three technically resectable liver metastases; three unilateral or two bilateral lung metastases; peritoneal carcinomatosis with PCI ≤ 6. No consensus was achieved on how to classify positive cytology, which was considered as oligometastatic by 55% of participants only if converted to negative after chemotherapy. Conclusion: As assessed at the time of diagnosis, surgical treatment of oligometastases should aim at R0 curativity on the entire disease volume, including both the primary tumor and its metastases. Conversion surgery was defined as surgery on the residual volume of disease, which was initially not resectable for technical and/or oncological reasons but nevertheless responded to first-line treatment.</p